Evidence map›Paper›PMID 27521413›Full record

ArticleCanadian family physician Medecin de famille canadien2016

Predicting chronic benzodiazepine use in adults with depressive disorder: Retrospective cohort study using administrative data in Quebec.

Jean-Daniel Carrier, Pasquale Roberge, Josiane Courteau, Alain Vanasse

Open access · greenAbstract read
In one paragraph

Article in Canadian family physician Medecin de famille canadien, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jean-Daniel CarrierPsychiatrist and is pursuing a doctoral degree in health sciences research at the University of Sherbrooke, supported by the Clinician Investigator Program of the Royal College of Physicians and Surgeons of Canada.
Pasquale RobergeProfessor in the family medicine department of the Faculté de médecine et des sciences de la santé at the University of Sherbrooke and a psychology researcher in the PRIMUS (Programme de recherche interdisciplinaire sur la médecine et l'utilisation des soins) research group affiliated with the Centre de recherche du Centre hospitalier universitaire de Sherbrooke.
Josiane CourteauScientific Assistant in the PRIMUS research group.
Alain VanasseClinician-Investigator and Tenured Professor in the family medicine department of the Faculté de médecine et des sciences de la santé at the University of Sherbrooke and Director of the PRIMUS research group. Alain.Vanasse@USherbrooke.ca.
Université de Sherbrooke · CACentre Hospitalier Universitaire de Sherbrooke · CAPrimus Consulting (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo identify predictive variables of incident chronic benzodiazepine (BZD) use that could be assessed by prescribing physicians.

designRetrospective cohort study using public health and drug insurance administrative data.

settingQuebec.

participantsNew adult BZD users from January 1, 1999, to March 31, 2006, with a diagnosis of depressive disorder in the previous year were included. Chronic BZD use was defined as BZD availability at least 50% of the days between day 181 and day 365 following initiation.

main outcome measuresPotential associations between chronic BZD use and age; sex; drug insurance status; recent hospitalization; comorbidity; presence of chronic pain; use of psychotropic medication; mental health diagnoses; number, type, and duration of BZDs prescribed; and the prescribing physician's specialty.

resultsSelection led to an exhaustive cohort of 13 688 patients aged 18 to 64 years, and 3683 aged 65 and older. For the 18 to 64 age group, the combination of disability insurance and more than 1 BZD increased the proportion of chronic users from 14.4% to 53.4%. For patients 65 and older, the main correlates of chronic BZD use included claiming more than 1 BZD (adjusted odds ratio 2.24, 99% CI 1.65 to 3.06) and recent hospitalization (adjusted odds ratio 1.70, 99% CI 1.38 to 2.10). Recently hospitalized older patients with a prescription duration of less than 8 days were the highest-risk group identified (57.8%).

conclusionPhysicians should be aware that patients are more likely to become chronic BZD users if they receive disability insurance or following a hospitalization. Combination of BZDs is a potentially problematic practice that could be increasing the risk of chronic use.

Indexed as

AdultAgedAnti-Anxiety AgentsBenzodiazepinesChronic PainComorbidityDepressive DisorderFemaleHospitalizationHumansInsurance, DisabilityLogistic ModelsMaleMiddle AgedOdds RatioQuebecAnti-Anxiety AgentsBenzodiazepines

Identifiers

PMID27521413
PMCPMC4982746
OpenAlexW2511624310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.